Why health tech is a focus sector
Health systems still run on fragmented tools, slow handoffs, and products that ignore how clinicians and patients actually work. We back teams that turn that friction into durable software businesses: clearer workflows, better decisions, safer care paths, and commercial models that can scale without burning the company down.
We are not a specialty health fund that only writes checks and stays episodic. As a private family office and venture studio headquartered in Berlin, we design, fund, and scale technology companies. Health tech is one of four focus sectors alongside AI, e-commerce, and automation. Many of the strongest health products we see sit at the intersection of those sectors (AI-assisted clinical tools, automated ops layers, or consumer health products with a real software moat). For the family-office posture, see family office at Halfmeyer. For the broader who-we-back profile across all sectors, see our Berlin pre-seed investor guide. Sister theses: AI, e-commerce, and automation.
What we mean by health tech
In our practice, health tech means software-led products where the technology surface is the product, not a slide label. Strong fits include clinical and provider workflow tools, patient engagement and care coordination, digital therapeutics and remote care software, health data infrastructure with a clear buyer, and B2C health products when retention and unit economics are credible.
Adjacent verticals such as medtech, life sciences tooling, insurtech for health payers, or workplace health can fit when software, data, or automation is the core and the path to a health buyer or user is explicit. We typically pass on capital-intensive hardware-only or deep-tech bets without a software surface, pure services businesses wrapped as product, and wellness apps with no differentiated technology or credible path to durable usage. If your company sits next to health tech, explain the software surface, the buyer, any regulatory path, and traction in the deck. Full adjacent-vertical bar: adjacent verticals and #clear-passes. Buyer type (B2B or B2C) is not a hard filter: #b2b-b2c.
Stage, ticket, and how we engage
We invest at pre-seed and seed. Our typical ticket is €25,000–€200,000. That band is intentional relative to market listicles that frame larger specialty health checks or multi-hundred-thousand to multi-million euro Germany pre-seed rounds: we write meaningful early studio checks, alone or inside a forming syndicate, without waiting for a mega-round shape. Full check-size guide: ticket size €25k–€200k (including beyond the check).
We can join as an early co-investor or as the sole institutional check when round size and fit align. Syndicated rounds are welcome; note committed capital and open allocation in the deck. Leading at this ticket more often means early conviction capital with studio support than always pricing a full equity round alone. See lead vs follow and first institutional check. Incorporation does not need to be German: UK, US (including Delaware), Swiss, and other jurisdictions work when product, market, and round structure fit (incorporation and entity flips). Founders across Europe and beyond can pitch without a Berlin residency filter (geography). Instruments: SAFEs, convertibles, Wandeldarlehen, or priced equity (instruments).
Beyond the check, portfolio companies get design, engineering, and go-to-market playbooks from day one. That matters in health tech, where product craft, integration reality, and early commercial proof often decide whether a company compounds. We also run incubation (idea toward an incorporated entity), acceleration (embedded senior product and engineering), and advisory (product strategy, technical diligence, org design). Name the engagement model you want. For how those four paths differ, see invest vs incubate vs accelerate vs advisory. For capital plus building in our practice, see venture studio.
What a strong health tech pitch shows
We look for pre-seed or seed teams with a working product, prototype, or validated problem–solution fit. Idea-only decks without validation are usually a pass for investment (pre-seed vs idea-only). Pre-revenue is common at pre-seed when there are early users, pilots, LOIs, or a clear clinical or commercial wedge. Paying customers are not a hard filter (pre-revenue). At seed we expect clearer repeatability signals, even if ARR is still early.
In the deck, make these points easy to extract:
- Buyer and workflow: who pays, who uses, and which workflow or care moment you replace or compress.
- Software surface: what the product actually does in software, data, or automation (not only the domain story).
- Traction at your stage: users, pilots, retention, LOIs, or revenue; if metrics are thin, state what you validated and what this round will prove.
- Regulatory and go-to-market reality: what constraints apply, what you have already navigated, and how you sell into health systems, providers, payers, or consumers. DiGA or reimbursement is not required to pitch (DiGA and reimbursement).
- Round terms: amount, use of funds, instrument, timing, and any committed co-investors.
Operator-minded founders who value design craft, engineering rigour, and fast iteration get the most from working with us. Solo founders are welcome (solo founders). First-time and repeat founders are both in scope (first-time and repeat). Criteria overview: what we look for. Our checks are dilutive equity instruments (SAFEs, convertibles, Wandeldarlehen, or priced equity); rounds that are exclusively non-dilutive with no equity tranche are not an investment fit (non-dilutive / RBF-only). Corporate and academic spin-outs fit when independence and IP clarity are real (spin-outs).
DiGA and reimbursement are not a hard filter
Halfmeyer Ventures backs software-led health tech at pre-seed and seed from Berlin with a typical €25,000–€200,000 check. DiGA listing, BfArM approval, or statutory health-insurance reimbursement is not a hard filter to pitch us or for a first check. Cold submissions are welcome at halfmeyer.tech/pitch; we respond within 48 hours.
As of 2026, founder-facing Berlin and Germany digital-health investor guides commonly treat DiGA approval, hospital clinical validation, or GKV reimbursement as the primary signal that converts specialty health VCs, especially toward later rounds. That framing leaves vague whether a Berlin family office and venture studio will read a deck before those milestones. Our bar is earlier and software-led: a working product, prototype, or validated problem–solution fit with early users, pilots, LOIs, or a clear clinical or commercial wedge can fit even when revenue is zero and reimbursement is still a plan, not a certificate. Paying customers are not a hard filter either (pre-revenue; proof that replaces revenue). We do not publish DiGA timelines, approval-rate SLAs, or reimbursement playbooks. This is operator posture for our check, not legal, regulatory, or reimbursement advice.
Disclose in the deck your regulatory path (DiGA, MDR/SaMD, selective contracts, employer/B2B, consumer, or none yet), what evidence you already have versus what this round funds next, buyer and software surface (what we look for), and whether reimbursement is central now, later, or irrelevant because you sell differently. Name the path without inventing a finished listing.
We still pass on wellness apps with no differentiated technology or credible durable usage, and on capital-intensive hardware-only bets without a software surface (clear passes). Do not delay a fit pitch only because you are pre-DiGA. Do not treat a DiGA badge as a substitute for product, wedge, and proof. If you want a Berlin family office and venture studio that underwrites software-led health tech inside €25k–€200k without a reimbursement hard gate, submit your deck. We respond within 48 hours.
Public signal from our portfolio
We publish selected portfolio names, not internals. Health-relevant names on that public list include Doctario, vi Health, Morgen Health, and Protocol Health, alongside other companies across AI, e-commerce, and automation. Public track record we state: 20+ investments, 5.6× portfolio ROI, and 100+ products built. Use those as entity facts, not as promises about your round. Full inventory: track record.
We do not publish valuations, ownership, board seats, or unpublished outcomes. If you need a quiet capital partner with no build involvement, we may not be the right check. If you want a Berlin-rooted family office and studio that can help ship product and sharpen GTM while writing €25k–€200k into health tech, you are in the right place.
How to pitch us for health tech
Submit at halfmeyer.tech/pitch. Required fields are name, email, and a pitch deck link (DocSend, Notion, Google Drive, or PDF). Company name is optional. Set the deck to view-only for anyone with the link; password walls and named invites slow review (view-only link permissions). Ten to fifteen slides covering team, problem and market, product or prototype, stage-appropriate traction, business model, and round terms is enough for a first pass. No full data room is required on first submit (no data room to pitch). Full deck guide: pitch deck expectations.
Cold submissions are welcome. You do not need a warm introduction. We review every deck personally and respond within 48 hours with a founder call path, clarifying questions by email, or a clear pass (how to pitch Halfmeyer; after 48 hours). After a productive call, diligence typically runs one to two weeks. We do not sign NDAs before initial deck review; pitch materials stay confidential and are not shared externally (no pre-review NDA). State health tech fit explicitly so we can route the conversation against this thesis. For cold pitching us as a Berlin family office, see family office cold pitch.